Congratulations to our client, HepaRegeniX GmbH on their appointment of Christoph Enderle to the role of Fractional CFO.
Since 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). The first MKK4 inhibitor HRX-215 recently completed Phase 1 clinical testing. MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tuebingen, Germany. Investors in HepaRegeniX include Vesalius Biocapital IV, the Boehringer Ingelheim Venture Fund (BIVF), Seed Investments – Novo Holdings A/S, coparion, HTGF | High-Tech Gründerfonds and Ascenion GmbH.
C1 Team: Christos Richards, Antonia Halliday and Anna Naylor